Concepts (70)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oligonucleotides, Antisense | 3 | 2005 | 137 | 0.110 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2004 | 41 | 0.110 |
Why?
|
| Janus Kinase 3 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Dry Eye Syndromes | 1 | 2012 | 4 | 0.100 |
Why?
|
| Pyrroles | 1 | 2012 | 47 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2012 | 131 | 0.090 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 750 | 0.080 |
Why?
|
| Hair Follicle | 1 | 2005 | 29 | 0.060 |
Why?
|
| Breast Neoplasms, Male | 1 | 2004 | 14 | 0.060 |
Why?
|
| Estradiol | 1 | 2004 | 247 | 0.050 |
Why?
|
| Folic Acid | 1 | 2003 | 41 | 0.050 |
Why?
|
| Liposomes | 1 | 2003 | 100 | 0.050 |
Why?
|
| Skin | 1 | 2005 | 357 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2003 | 201 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 289 | 0.040 |
Why?
|
| Administration, Topical | 2 | 2012 | 48 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2012 | 645 | 0.030 |
Why?
|
| Biological Transport | 2 | 2005 | 288 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2004 | 450 | 0.030 |
Why?
|
| Tears | 1 | 2012 | 4 | 0.020 |
Why?
|
| Ophthalmic Solutions | 1 | 2012 | 7 | 0.020 |
Why?
|
| Conjunctiva | 1 | 2012 | 3 | 0.020 |
Why?
|
| Cell Division | 2 | 2004 | 443 | 0.020 |
Why?
|
| HLA-DR1 Antigen | 1 | 2012 | 27 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2012 | 76 | 0.020 |
Why?
|
| Time Factors | 3 | 2005 | 3620 | 0.020 |
Why?
|
| Piperidines | 1 | 2012 | 55 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 805 | 0.020 |
Why?
|
| Cytokines | 1 | 2012 | 912 | 0.020 |
Why?
|
| Mice | 3 | 2005 | 10300 | 0.020 |
Why?
|
| Mice, Hairless | 1 | 2005 | 17 | 0.020 |
Why?
|
| Operator Regions, Genetic | 1 | 2004 | 6 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2004 | 25 | 0.010 |
Why?
|
| Tetracycline | 1 | 2004 | 22 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 259 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 223 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 279 | 0.010 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2003 | 2 | 0.010 |
Why?
|
| KB Cells | 1 | 2003 | 15 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 16 | 0.010 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2003 | 10 | 0.010 |
Why?
|
| Thionucleotides | 1 | 2003 | 38 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2003 | 98 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 868 | 0.010 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2003 | 11 | 0.010 |
Why?
|
| Cyclins | 1 | 2003 | 40 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 52 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 148 | 0.010 |
Why?
|
| G1 Phase | 1 | 2003 | 55 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 287 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 30 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 300 | 0.010 |
Why?
|
| Serine | 1 | 2003 | 84 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 106 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 145 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 226 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 473 | 0.010 |
Why?
|
| Animals | 3 | 2005 | 19664 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2003 | 374 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 652 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 584 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 428 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 885 | 0.010 |
Why?
|
| Humans | 4 | 2012 | 59424 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2003 | 697 | 0.010 |
Why?
|
| Male | 2 | 2012 | 27772 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 1143 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1469 | 0.010 |
Why?
|
| Middle Aged | 1 | 2012 | 16330 | 0.010 |
Why?
|
| Female | 1 | 2012 | 30753 | 0.010 |
Why?
|